drugset / Trial / NCT00936858
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Phase 2
Completed
50 enrolled
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center · collabMOUNT SINAI HOSPITAL · collabMassachusetts General Hospital · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
Since thyroid cancer becomes refractory to radioactive iodine, treatment options are very limited. Tyrosine kinase inhibitors such as sorafenib have recently shown promise. This trial seeks to expand treatment options for this disease with a new, oral drug called RAD001. It is an inhibitor of the mTOR pathway and has shown activity in neuroendocrine cancers of the gastrointestinal tract and has been approved for the treatment of metastatic renal cell cancer.
Timeline
- Start
- 2009-07
- Primary completion
- 2020-02-27
- Completion
- 2020-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 10 mg | Oral |